Global Guide of Coming Off-patent Agrochemical Active Ingredients Edition (3)

Publisher Name :
Date: 23-Sep-2016
No. of pages: 198
Inquire Before Buying

Penoxsulam, developed and produced by Dow AgroSciences LLC (Dow AgroSciences), is a trizolopyrimidine herbicide applied in paddy fields with the widest herbicidal spectrum. It has great effect not only on aquatic weeds but also on barnyard grass which has resistance to herbicides like quinclorac, propanil and sulfonylurea.

Penoxsulam was registered in U.S. Environmental Protection Agency in 2004; later in 2005, it got promoted and applied in paddy fields in the southern US in 2005.

In 2006, penoxsulam was used in Spain, Brazil, Columbia, South Korea and Thailand.

In 2007, it was registered in Japan and China. In 2009, penoxsulam finally entered the Chinese market.

"After years of development, penoxsulam enjoys a very potential future in the market," stated Chen Zaoqun, chief editor of Herbicide China News, CCM.

In fact, when penoxsulam first came into the market, the global sales volume was less than USD10 million, but in 2009, the sales volumes reached USD110 million. In 2013, the sales volume climbed to about USD225 million.

Penoxsulam also has a great performance in weed control in non-agriculture market such as in lawns and in orchards. In 2013, the sale volume of penoxsulam applied in non-agriculture market reached about USD140 million, which surpassed that of those applied in paddy fields, USD110 million.

Currently, most of the penoxsulam is applied on paddy fields and the paddy cultivation countries are mainly in Asia-Pacific and East Africa. Those markets belong to middle- and low-end market; thus, it is not difficult for enterprises to register penoxsulam products.

"Penoxsulam' great effect in weeds control makes it be needed in the market and it would be consumed most in Asia-Pacific in the next five years," Chen commented.

Besides, according to CCM's research, there is no substitute product for penoxsulam; thus, penoxsulam would be the key product in weeds control in paddy fields.

If you are interested in finding out the information on coming off-patent agrochemical active ingredients in different countries, you could have a look at our report: Global Guide of Coming Off-patent Agrochemical Active Ingredients.

In this report, you will be able to find the profiles of 36 active ingredients (11 herbicides, 8 insecticides, 17 fungicides) whose patents had been or will be expired during 2015-2020. Each profile of the agrochemical active ingredients includes basic information, history, synthesis route, application, physical & safety data, patent information and registration information in 15 target countries (Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Denmark, Finland, France, Greece, the Netherlands, South Africa, Switzerland and Uruguay).

Every client could directly talk to our research team after choosing our report.

Companies Mentioned


  • Syngenta Canada Inc.

  • Bayer CropScience Inc.

  • LG Life Science, Ltd.

  • Kriltec S.A.

  • Tampa S.A.

Global Guide of Coming Off-patent Agrochemical Active Ingredients Edition (3)

Table of Contents

Executive summary
Methodology and scope

1 Profiles of coming off-patent herbicides
1.1 Flucetosulfuron
1.2 Flufenpyr-ethyl
1.3 Foramsulfuron
1.4 Metamifop
1.5 Orthosulfamuron
1.6 Penoxsulam
1.7 Pinoxaden
1.8 Propoxycarbazone
1.9 Tembotrione
1.10 Thiencarbazone-methyl
1.11 Topramezone

2 Profiles of coming off-patent insecticides
2.1 Bistrifluron
2.2 Clothianidin
2.3 Ethiprole
2.4 Flubendiamide
2.5 Metofluthrin
2.6 Pyridalyl
2.7 Pyrifluquinazon
2.8 Spirotetramat

3 Profiles of coming off-patent fungicides
3.1 Amisulbrom
3.2 Benalaxyl-M
3.3 Benthiavalicarb-isopropyl
3.4 Cyflufenamid
3.5 Dimoxystrobin
3.6 Fenpyrazamine
3.7 Fluopicolide
3.8 Fluoxastrobin
3.9 Isotianil
3.10 Metalaxyl-M
3.11 Metrafenone
3.12 Orysastrobin
3.13 Penthiopyrad
3.14 Prothioconazole
3.15 Pyraclostrobin
3.16 Silthiofam
3.17 Valifenalate

List of Tables

Table 1.1-1 Patent information of flucetosulfuron in some countries/regions, as of Aug. 2016
Table 1.1-2 Registration information of flucetosulfuron in China, as of Aug. 2016
Table 1.2-1 Patent information of flufenpyr-ethyl in some countries/regions, as of Aug. 2016
Table 1.3-1 Patent information of foramsulfuron in some countries/regions, as of Aug. 2016
Table 1.3-2 Registration information of foramsulfuron in Argentina, as of Aug. 2016
Table 1.3-3 Registration information of foramsulfuron in Denmark, as of Aug. 2016
Table 1.3-4 Registration information of foramsulfuron in Australia, as of Aug. 2016
Table 1.3-5 Registration information of foramsulfuron in Belgium, as of Aug. 2016
Table 1.3-6 Registration information of foramsulfuron in Canada, as of Aug. 2016
Table 1.3-7 Registration information of foramsulfuron in Chile, as of Aug. 2016
Table 1.3-8 Registration information of foramsulfuron in France, as of Aug. 2016
Table 1.3-9 Registration information of foramsulfuron in Greece, as of Aug. 2016
Table 1.3-10 Registration information of foramsulfuron in the Netherlands, as of Aug. 2016
Table 1.3-11 Registration information of foramsulfuron in Switzerland, as of Aug. 2016
Table 1.3-12 Registration information of foramsulfuron in Uruguay, as of Aug. 2016
Table 1.4-1 Patent information of metamifop in some countries/regions, as of Aug. 2016
Table 1.4-2 Registration information of metamifop in China, as of Aug. 2016
Table 1.4-3 Registration information of metamifop in Uruguay, as of Aug. 2016
Table 1.5-1 Patent information of orthosulfamuron in some countries/regions, as of Aug. 2016
Table 1.5-2 Registration information of orthosulfamuron in China, as of Aug. 2016
Table 1.6-1 Patent information of penoxsulam in some countries/regions, as of Aug. 2016
Table 1.6-2 Registration information of penoxsulam in Argentina, as of Aug. 2016
Table 1.6-3 Registration information of penoxsulam in Brazil, as of Aug. 2016
Table 1.6-4 Registration information of penoxsulam in Chile, as of Aug. 2016
Table 1.6-5 Registration information of penoxsulam in China, as of Aug. 2016
Table 1.6-6 Registration information of penoxsulam in France, as of Aug. 2016
Table 1.6-7 Registration information of penoxsulam in Greece, as of Aug. 2016
Table 1.6-8 Registration information of penoxsulam in Switzerland, as of Aug. 2016
Table 1.6-9 Registration information of penoxsulam in Uruguay, as of Aug. 2016
Table 1.7-1 Patent information of pinoxaden in some countries/regions, as of Aug. 2016
Table 1.7-2 Registration information of pinoxaden in Argentina, as of Aug. 2016
Table 1.7-3 Registration information of pinoxaden in Denmark, as of Aug. 2016
Table 1.7-4 Registration information of pinoxaden in South Africa, as of Aug. 2016
Table 1.7-5 Registration information of pinoxaden in Australia, as of Aug. 2016
Table 1.7-6 Registration information of pinoxaden in Belgium, as of Aug. 2016
Table 1.7-7 Registration information of pinoxaden in Canada, as of Aug. 2016
Table 1.7-8 Registration information of pinoxaden in Chile, as of Aug. 2016
Table 1.7-9 Registration information of pinoxaden in China, as of Aug. 2016
Table 1.7-10 Registration information of pinoxaden in Finland, as of Aug. 2016
Table 1.7-11 Registration information of pinoxaden in France, as of Aug. 2016
Table 1.7-12 Registration iunformation of pinoxaden in Greece, as of Aug. 2016
Table 1.7-13 Registration information of pinoxaden in the Netherlands, as of Aug. 2016
Table 1.7-14 Registration information of pinoxaden in Switzerland, as of Aug. 2016
Table 1.7-15 Registration information of pinoxaden in Uruguay, as of Aug. 2016
Table 1.8-1 Patent information of propoxycarbazone in some countries/regions, as of Aug. 2016
Table 1.8-2 Registration information of propoxycarbazone in Belgium, as of Aug. 2016
Table 1.8-3 Registration information of propoxycarbazone in Denmark, as of Aug. 2016
Table 1.8-4 Registration information of propoxycarbazone in Finland, as of Aug. 2016
Table 1.8-5 Registration information of propoxycarbazone in France, as of Aug. 2016
Table 1.8-6 Registration information of propoxycarbazone in Greece, as of Aug. 2016
Table 1.8-7 Registration information of propoxycarbazone in Canada, as of Aug. 2016
Table 1.9-1 Patent information of tembotrione in some countries/regions, as of Aug. 2016
Table 1.9-2 Registration information of tembotrione in Belgium, as of Aug. 2016
Table 1.9-3 Registration information of tembotrione in South Africa, as of Aug. 2016
Table 1.9-4 Registration information of tembotrione in Canada, as of Aug. 2016
Table 1.9-5 Registration information of tembotrione in Chile, as of Aug. 2016
Table 1.9-6 Registration information of tembotrione in France, as of Aug. 2016
Table 1.9-7 Registration information of tembotrione in Greece, as of Aug. 2016
Table 1.9-8 Registration information of tembotrione in the Netherlands, as of Aug. 2016
Table 1.9-9 Registration information of tembotrione in Switzerland, as of Aug. 2016
Table 1.10-1 Patent information of thiencarbazone-methyl in some countries/regions, as of Aug. 2016
Table 1.10-2 Registration information of thiencarbazone-methyl in Belgium, as of Aug. 2016
Table 1.10-3 Registration information of thiencarbazone-methyl in Canada, as of Aug. 2016
Table 1.10-4 Registration information of thiencarbazone-methyl in France, as of Aug. 2016
Table 1.10-5 Registration information of thiencarbazone-methyl in Greece, as of Aug. 2016
Table 1.10-6 Registration information of thiencarbazone-methyl in Switzerland, as of Aug. 2016
Table 1.10-7 Registration information of thiencarbazone-methyl in the Netherlands, as of Aug. 2016
Table 1.10-8 Registration information of thiencarbazone-methyl in Uruguay, as of Aug. 2016
Table 1.10-9 Registration information of thiencarbazone-methyl in China, as of Aug. 2016
Table 1.11-1 Patent information of topramezone in some countries/regions, as of Aug. 2016
Table 1.11-2 Registration information of topramezone in Argentina, as of Aug. 2016
Table 1.11-3 Registration information of topramezone in Belgium, as of Aug. 2016
Table 1.11-4 Registration information of topramezone in South Africa, as of Aug. 2016
Table 1.11-5 Registration information of topramezone in Canada, as of Aug. 2016
Table 1.11-6 Registration information of topramezone in Chile, as of Aug. 2016
Table 1.11-7 Registration information of topramezone in China, as of Aug. 2016
Table 1.11-8 Registration information of topramezone in Greece, as of Aug. 2016
Table 1.11-9 Registration information of topramezone in Uruguay, as of Aug. 2016
Table 1.11-10 Registration information of topramezone in the Netherlands, as of Aug. 2016
Table 2.1-1 Patent information of bistrifluron in some countries/regions, as of Aug. 2016
Table 2.1-2 Registration information of bistrifluron in Australia, as of Aug. 2016
Table 2.1-3 Registration information of bistrifluron in Argentina, as of Aug. 2016
Table 2.2-1 Patent information of clothianidin in some countries/regions, as of Aug. 2016
Table 2.2-2 Registration information of clothianidin in Argentina, as of Aug. 2016
Table 2.2-3 Registration information of clothianidin in Chile, as of Aug. 2016
Table 2.2-4 Registration information of clothianidin in Denmark, as of Aug. 2016
Table 2.2-5 Registration information of clothianidin in South Africa, as of Aug. 2016
Table 2.2-6 Registration information of clothianidin in Australia, as of Aug. 2016
Table 2.2-7 Registration information of clothianidin in Belgium, as of Aug. 2016
Table 2.2-8 Registration information of clothianidin in Brazil, as of Aug. 2016
Table 2.2-9 Registration information of clothianidin in Canada, as of Aug. 2016
Table 2.2-10 Registration information of clothianidin in China, as of Aug. 2016
Table 2.2-11 Registration information of clothianidin in Finland, as of Aug. 2016
Table 2.2-12 Registration information of clothianidin in Greece, as of Aug. 2016
Table 2.2-13 Registration information of clothianidin in the Netherlands, as of Aug. 2016
Table 2.2-14 Registration information of clothianidin in Switzerland, as of Aug. 2016
Table 2.2-15 Registration information of clothianidin in Uruguay, as of Aug. 2016
Table 2.2-16 Registration information of clothianidin in France, as of Aug. 2016
Table 2.3-1 Patent information of ethiprole in some countries/regions, as of Aug. 2016
Table 2.3-2 Registration information of ethiprole in China, as of Aug. 2016
Table 2.4-1 Patent information of flubendiamide in some countries/regions, as of Aug. 2016
Table 2.4-2 Registration information of flubendiamide in Argentina, as of Aug. 2016
Table 2.4-3 Registration information of flubendiamide in Australia, as of Aug. 2016
Table 2.4-4 Registration information of flubendiamide in South Africa, as of Aug. 2016
Table 2.4-5 Registration information of flubendiamide in Chile, as of Aug. 2016
Table 2.4-6 Registration information of flubendiamide in China, as of Aug. 2016
Table 2.4-7 Registration information of flubendiamide in Greece, as of Aug. 2016
Table 2.4-8 Registration information of flubendiamide in the Netherlands, as of Aug. 2016
Table 2.4-9 Registration information of flubendiamide in Uruguay, as of Aug. 2016
Table 2.4-10 Registration information of flubendiamide in Brazil, as of Aug. 2016
Table 2.5-1 Patent information of metofluthrin in some countries/regions, as of Aug. 2016
Table 2.5-2 Registration information of metofluthrin in Australia, as of Aug. 2016
Table 2.5-3 Registration information of metofluthrin in Canada, as of Aug. 2016
Table 2.5-4 Registration information of metofluthrin in China, as of Aug. 2016
Table 2.5-5 Registration information of metofluthrin in the Netherlands, as of Aug. 2016
Table 2.6-1 Patent information of pyridalyl in some countries/regions, as of Aug. 2016
Table 2.6-2 Registration information of pyridalyl in China, as of Aug. 2016
Table 2.6-3 Registration information of pyridalyl in South Africa, as of Aug. 2016
Table 2.6-4 Registration information of pyridalyl in the Netherlands, as of Aug. 2016
Table 2.7-1 Patent information of pyrifluquinazon in some countries/regions, as of Aug. 2016
Table 2.8-1 Patent information of spirotetramat in some countries/regions, as of Aug. 2016
Table 2.8-2 Registration information of spirotetramat in Australia, as of Aug. 2016
Table 2.8-3 Registration information of spirotetramat in Denmark, as of Aug. 2016
Table 2.8-4 Registration information of spirotetramat in South Africa, as of Aug. 2016
Table 2.8-5 Registration information of spirotetramat in Belgium, as of Aug. 2016
Table 2.8-6 Registration information of spirotetramat in Canada, as of Aug. 2016
Table 2.8-7 Registration information of spirotetramat in Chile, as of Aug. 2016
Table 2.8-8 Registration information of spirotetramat in China, as of Aug. 2016
Table 2.8-9 Registration information of spirotetramat in France, as of Aug. 2016
Table 2.8-10 Registration information of spirotetramat in Greece, as of Aug. 2016
Table 2.8-11 Registration information of spirotetramat in the Netherlands, as of Aug. 2016
Table 2.8-12 Registration information of spirotetramat in Uruguay, as of Aug. 2016
Table 2.8-13 Registration information of spirotetramat in Switzerland, as of Aug. 2016
Table 3.1-1 Patent information of amisulbrom in some countries/regions, as of Aug. 2016
Table 3.1-2 Registration information of amisulbrom in Belgium, as of Aug. 2016
Table 3.1-3 Registration information of amisulbrom in Denmark, as of Aug. 2016
Table 3.1-4 Registration information of amisulbrom in Finland, as of Aug. 2016
Table 3.1-5 Registration information of amisulbrom in the Netherlands, as of Aug. 2016
Table 3.1-6 Registration information of amisulbrom in Switzerland, as of Aug. 2016
Table 3.1-7 Registration information of amisulbrom in China, as of Aug. 2016
Table 3.1-8 Registration information of amisulbrom in Australia, as of Aug. 2016
Table 3.2-1 Patent information of benalaxyl-M in some countries/regions, as of Aug. 2016
Table 3.2-2 Registration information of benalaxyl-M in Argentina, as of Aug. 2016
Table 3.2-3 Registration information of benalaxyl-M in Australia, as of Aug. 2016
Table 3.2-4 Registration information of benalaxyl-M in Belgium, as of Aug. 2016
Table 3.2-5 Registration information of benalaxyl-M in Brazil, as of Aug. 2016
Table 3.2-6 Registration information of benalaxyl-M in Chile, as of Aug. 2016
Table 3.2-7 Registration information of benalaxyl-M in France, as of Aug. 2016
Table 3.2-8 Registration information of benalaxyl-M in Greece , as of Aug. 2016
Table 3.2-9 Registration information of benalaxyl-M in the Netherlands, as of Aug.2016
Table 3.2-10 Registration information of benalaxyl-M in Switzerland, as of Aug. 2016
Table 3.3-1 Patent information of benthiavalicarb-isopropyl in some countries/regions, as of Aug. 2016
Table 3.3-2 Registration information of benthiavalicarb-isopropyl in Belgium, as of Aug. 2016
Table 3.3-3 Registration information of benthiavalicarb-isopropyl in Denmark, as of Aug. 2016
Table 3.3-4 Registration information of benthiavalicarb-isopropyl in Greece, as of Aug. 2016
Table 3.3-5 Registration information of benthiavalicarb-isopropyl in the Netherlands, as of Aug. 2016
Table 3.3-6 Registration information of benthiavalicarb-isopropyl in Switzerland, as of Aug. 2016
Table 3.4-1 Patent information of cyflufenamid in some countries/regions, as of Aug. 2016
Table 3.4-2 Registration information of cyflufenamid in Australia, as of Aug. 2016
Table 3.4-3 Registration information of cyflufenamid in Denmark, as of Aug. 2016
Table 3.4-4 Registration information of cyflufenamid in South Africa, as of Aug. 2016
Table 3.4-5 Registration information of cyflufenamid in Belgium, as of Aug. 2016
Table 3.4-6 Registration information of cyflufenamid in Greece, as of Aug. 2016
Table 3.4-7 Registration information of cyflufenamid in the Netherlands, as of Aug. 2016
Table 3.4-8 Registration information of cyflufenamid in Switzerland, as of Aug. 2016
Table 3.4-9 Registration information of cyflufenamid in France, as of Aug. 2016
Table 3.5-1 Patent information of dimoxystrobin in some countries/regions, as of Aug. 2016
Table 3.5-2 Registration information of dimoxystrobin in Belgium, as of Aug. 2016
Table 3.5-3 Registration information of dimoxystrobin in Denmark, as of Aug. 2016
Table 3.5-4 Registration information of dimoxystrobin in France, as of Aug. 2016
Table 3.6-1 Patent information of fenpyrazamine in some countries/regions, as of Aug. 2016
Table 3.6-2 Registration information of fenpyrazamine in Australia, as of Aug. 2016
Table 3.6-3 Registration information of fenpyrazamine in Chile, as of Aug. 2016
Table 3.6-4 Registration information of fenpyrazamine in Denmark, as of Aug. 2016
Table 3.6-5 Registration information of fenpyrazamine in Belgium, as of Aug. 2016
Table 3.6-6 Registration information of fenpyrazamine in Switzerland, as of Aug. 2016
Table 3.6-7 Registration information of fenpyrazamine in France, as of Aug. 2016
Table 3.6-8 Registration information of fenpyrazamine in Greece, as of Aug. 2016
Table 3.6-9 Registration information of fenpyrazamine in the Netherlands, as of Aug. 2016
Table 3.7-1 Patent information of fluopicolide in some countries/regions, as of Aug. 2016
Table 3.7-2 Registration information of fluopicolide in Argentina, as of Aug. 2016
Table 3.7-3 Registration information of fluopicolide in Denmark, as of Aug. 2016
Table 3.7-4 Registration information of fluopicolide in South Africa, as of Aug. 2016
Table 3.7-5 Registration information of fluopicolide in Belgium, as of Aug. 2016
Table 3.7-6 Registration information of fluopicolide in Brazil, as of Aug. 2016
Table 3.7-7 Registration information of fluopicolide in Canada, as of Aug. 2016
Table 3.7-8 Registration information of fluopicolide in Chile, as of Aug. 2016
Table 3.7-9 Registration information of fluopicolide in China, as of Aug. 2016
Table 3.7-10 Registration information of fluopicolide in Finland, as of Aug. 2016
Table 3.7-11 Registration information of fluopicolide in France, as of Aug. 2016
Table 3.7-12 Registration information of fluopicolide in Greece, as of Aug. 2016
Table 3.7-13 Registration information of fluopicolide in the Netherlands, as of Aug.2016
Table 3.7-14 Registration infromation of fluopicolide in Switzerland, as of Aug. 2016
Table 3.7-15 Registration information of fluopicolide in Uruguay, as of Aug. 2016
Table 3.8-1 Patent information of fluoxastrobin in some countries/regions, as of Aug. 2016
Table 3.8-2 Registration information of fluoxastrobin in Argentina, as of Aug. 2016
Table 3.8-3 Registration information of fluoxastrobin in Belgium, as of Aug. 2016
Table 3.8-4 Registration information of fluoxastrobin in Chile, as of Aug. 2016
Table 3.8-5 Registration information of fluoxastrobin in Denmark, as of Aug. 2016
Table 3.8-6 Registration information of fluoxastrobin in Canada, as of Aug. 2016
Table 3.8-7 Registration information of fluoxastrobin in France, as of Aug. 2016
Table 3.8-8 Registration information of fluoxastrobin in the Netherlands, as of Aug. 2016
Table 3.8-9 Registration information of fluoxastrobin in Switzerland, as of Aug. 2016
Table 3.8-10 Registration information of fluoxastrobin in Uruguay, as of Aug. 2016
Table 3.8-11 Registration information of fluoxastrobin in China, as of Aug. 2016
Table 3.8-12 Registration information of fluoxastrobin in Greece, as of Aug. 2016
Table 3.9-1 Patent information of isotianil in some countries/regions, as of Aug. 2016
Table 3.10-1 Patent information of metalaxyl-M in some countries/regions, as of Aug. 2016
Table 3.10-2 Registration information of metalaxyl-M in Argentina, as of Aug. 2016
Table 3.10-3 Registration information of metalaxyl-M in Chile, as of Aug. 2016
Table 3.10-4 Registration information of metalaxyl-M in Denmark, as of Aug. 2016
Table 3.10-5 Registration information of metalaxyl-M in South Africa, as of Aug. 2016
Table 3.10-6 Registration information of metalaxyl-M in Australia, as of Aug. 2016
Table 3.10-7 Registration information of metalaxyl-M in Belgium, as of Aug. 2016
Table 3.10-8 Registration information of metalaxyl-M in Brazil, as of Aug. 2016
Table 3.10-9 Registration information of metalaxyl-M in Canada, as of Aug. 2016
Table 3.10-10 Registration information of metalaxyl-M in China, as of Aug. 2016
Table 3.10-11 Registration information of metalaxyl-M in Finland, as of Aug. 2016
Table 3.10-12 Registration information of metalaxyl-M in Greece, as of Aug. 2016
Table 3.10-13 Registration information of metalaxyl-M in the Netherlands, as of Aug. 2016
Table 3.10-14 Registration information of metalaxyl-M in Switzerland, as of Aug. 2016
Table 3.10-15 Registration information of metalaxyl-M in Uruguay, as of Aug. 2016
Table 3.10-16 Registration information of metalaxyl-M in France, as of Aug. 2016
Table 3.11-1 Patent information of metrafenone in some countries/regions, as of Aug. 2016
Table 3.11-2 Registration information of metrafenone in Australia, as of Aug. 2016
Table 3.11-3 Registration information of metrafenone in Denmark, as of Aug. 2016
Table 3.11-4 Registration information of metrafenone in South Africa, as of Aug. 2016
Table 3.11-5 Registration information of metrafenone in Belgium, as of Aug. 2016
Table 3.11-6 Registration information of metrafenone in Canada, as of Aug. 2016
Table 3.11-7 Registration information of metrafenone in Chile, as of Aug. 2016
Table 3.11-8 Registration information of metrafenone in Greece, as of Aug. 2016
Table 3.11-9 Registration information of metrafenone in Switzerland, as of Aug. 2016
Table 3.11-10 Registration information of metrafenone in China, as of Aug. 2016
Table 3.11-11 Registration information of metrafenone in the Netherlands, as of Aug. 2016
Table 3.11-12 Registration information of metrafenone in France, as of Aug. 2016
Table 3.12-1 Patent information of orysastrobin in some countries/regions, as of Aug. 2016
Table 3.13-1 Patent information of penthiopyrad in some countries/regions, as of Aug. 2016
Table 3.13-2 Registration information of penthiopyrad in Argentina, as of Aug. 2016
Table 3.13-3 Registration information of penthiopyrad in Australia, as of Aug. 2016
Table 3.13-4 Registration information of penthiopyrad in France, as of Aug. 2016
Table 3.13-5 Registration information of penthiopyrad in Canada, as of Aug. 2016
Table 3.13-6 Registration information of penthiopyrad in Greece, as of Aug. 2016
Table 3.13-7 Registration information of penthiopyrad in the Netherlands, as of Aug. 2016
Table 3.13-8 Registration information of penthiopyrad in Switzerland, as of Aug. 2016
Table 3.14-1 Patent information of prothioconazole in some countries/regions, as of Aug. 2016
Table 3.14-2 Registration information of prothioconazole in Argentina, as of Aug. 2016
Table 3.14-3 Registration information of prothioconazole in Chile, as of Aug. 2016
Table 3.14-4 Registration information of prothioconazole in Denmark, as of Aug.2016
Table 3.14-5 Registration information of prothioconazole in South Africa, as of Aug. 2016
Table 3.14-6 Registration information of prothioconazole in Australia, as of Aug. 2016
Table 3.14-7 Registration information of prothioconazole in Brazil, as of Aug. 2016
Table 3.14-8 Registration information of prothioconazole in Canada, as of Aug. 2016
Table 3.14-9 Registration information of prothioconazole in Finland, as of Aug. 2016
Table 3.14-10 Registration information of prothioconazole in France, as of Aug. 2016
Table 3.14-11 Registration information of prothioconazole in Greece, as of Aug. 2016
Table 3.14-12 Registration information of prothioconazole in the Netherlands, as of Aug. 2016
Table 3.14-13 Registration information of prothioconazole in Belgium, as of Aug. 2016
Table 3.14-14 Registration information of prothioconazole in Switzerland, as of Aug. 2016
Table 3.15-1 Patent information of pyraclostrobin in some countries/regions, as of Aug. 2016
Table 3.15-2 Registration information of pyraclostrobin in Argentina, as of Aug. 2016
Table 3.15-3 Registration information of pyraclostrobin in Chile, as of Aug. 2016
Table 3.15-4 Registration information of pyraclostrobin in South Africa, as of Aug. 2016
Table 3.15-5 Registration information of pyraclostrobin in Australia, as of Aug. 2016
Table 3.15-6 Registration information of pyraclostrobin in Belgium, as of Aug. 2016
Table 3.15-7 Registration information of pyraclostrobin in Canada, as of Aug. 2016
Table 3.15-8 Registration information of pyraclostrobin in China, as of Aug. 2016
Table 3.15-9 Registration information of pyraclostrobin in Denmark, as of Aug. 2016
Table 3.15-10 Registration information of pyraclostrobin in Finland, as of Aug. 2016
Table 3.15-11 Registration information of pyraclostrobin in France, as of Aug. 2016
Table 3.15-12 Registration information of pyraclostrobin in Greece, as of Aug. 2016
Table 3.15-13 Registration information of pyraclostrobin in the Netherlands, as of Aug. 2016
Table 3.15-14 Registration information of pyraclostrobin in South Africa, as of Aug. 2016
Table 3.15-15 Registration information of pyraclostrobin in Switzerland, as of Aug. 2016
Table 3.15-16 Registration information of pyraclostrobin in Uruguay, as of Aug. 2016
Table 3.15-17 Registration information of pyraclostrobin in Brazil, as of Aug. 2016
Table 3.16-1 Patent information of silthiofam in some countries/regions, as of Aug. 2016
Table 3.16-2 Registration information of silthiofam in Belgium, as of Aug. 2016
Table 3.16-3 Registration information of silthiofam in Chile, as of Aug. 2016
Table 3.16-4 Registration information of silthiofam in China, as of Aug. 2016
Table 3.16-5 Registration information of silthiofam in Denmark, as of Aug. 2016
Table 3.16-6 Registration information of silthiofam in the Netherlands, as of Aug. 2016
Table 3.16-7 Registration information of silthiofam in France, as of Aug. 2016
Table 3.17-1 Patent information of valifenalate in some countries/regions, as of Aug. 2016
Table 3.17-2 Registration information of valifenalate in Belgium, as of Aug. 2016
Table 3.17-3 Registration information of valifenalate in France, as of Aug. 2016
Table 3.17-4 Registration information of valifenalate in Switzerland, as of Aug. 2016

List of Figures

Figure 1.1-1 Chemical structure of flucetosulfuron
Figure 1.1-2 Route for synthesizing flucetosulfuron
Figure 1.2-1 Chemical structure of flufenpyr-ethyl
Figure 1.2-2 Route for synthesizing flufenpyr-ethyl
Figure 1.3-1 Chemical structure of foramsulfuron
Figure 1.3-2 Route A for synthesizing foramsulfuron
Figure 1.3-3 Route B for synthesizing foramsulfuron
Figure 1.3-4 Route C for synthesizing foramsulfuron
Figure 1.3-5 Route D for synthesizing foramsulfuron
Figure 1.4-1 Chemical structure of metamifop
Figure 1.4-2 Route for synthesizing metamifop
Figure 1.5-1 Chemical structure of orthosulfamuron
Figure 1.5-2 Route A for synthesizing orthosulfamuron
Figure 1.5-3 Route B for synthesizing orthosulfamuron
Figure 1.6-1 Chemical structure of penoxsulam
Figure 1.6-2 Route A for synthesizing penoxsulam
Figure 1.6-3 Route B for synthesizing penoxsulam
Figure 1.7-1 Chemical structure of pinoxaden
Figure 1.7-2 Route for synthesizing pinoxaden
Figure 1.8-1 Chemical structure of propoxycarbazone
Figure 1.8-2 Route for synthesizing propoxycarbazone
Figure 1.9-1 Chemical structure of tembotrione
Figure 1.9-2 Route for synthesizing tembotrione
Figure 1.10-1 Chemical structure of thiencarbazone-methyl
Figure 1.11-1 Chemical structure of topramezone
Figure 1.11-2 Route for synthesizing topramezone
Figure 2.1-1 Chemical structure of bistrifluron
Figure 2.1-2 Route for synthesizing bistrifluron
Figure 2.2-1 Chemical structure of clothianidin
Figure 2.2-2 Route A for synthesizing clothianidin
Figure 2.2-3 Route B for synthesizing clothianidin
Figure 2.2-4 Route C for synthesizing clothianidin
Figure 2.2-5 Route D for synthesizing clothianidin
Figure 2.3-1 Chemical structure of ethiprole
Figure 2.4-1 Chemical structure of flubendiamide
Figure 2.5-1 Chemical structure of metofluthrin
Figure 2.5-2 Route for synthesizing metofluthrin
Figure 2.6-1 Chemical structure of pyridalyl
Figure 2.6-2 Route A for synthesizing pyridalyl
Figure 2.6-3 Route B for synthesizing pyridalyl
Figure 2.6-4 Route C for synthesizing pyridalyl
Figure 2.7-1 Chemical structure of pyrifluquinazon
Figure 2.8-1 Chemical structure of spirotetramat
Figure 2.8-2 Synthesis route of spirotetramat
Figure 3.1-1 Chemical structure of amisulbrom
Figure 3.2-1 Chemical structure of benalaxyl-M
Figure 3.2-2 Route A for synthesizing benalaxyl-M
Figure 3.2-3 Route A for synthesizing benalaxyl-M
Figure 3.3-1 Chemical structure of benthiavalicarb-isopropyl
Figure 3.3-2 Route for synthesizing benthiavalicarb-isopropyl
Figure 3.4-1 Chemical structure of cyflufenamid
Figure 3.4-2 Route for synthesizing cyflufenamid
Figure 3.5-1 Chemical structure of dimoxystrobin
Figure 3.5-2 Route for synthesizing dimoxystrobin
Figure 3.6-1 Chemical structure of fenpyrazamine
Figure 3.7-1 Chemical structure of fluopicolide
Figure 3.7-2 Route A for synthesizing fluopicolide
Figure 3.7-3 Route B for synthesizing fluopicolide
Figure 3.8-1 Chemical structure of fluoxastrobin
Figure 3.8-2 Route A for synthesizing fluoxastrobin
Figure 3.8-3 Route B for synthesizing fluoxastrobin
Figure 3.9-1 Chemical structure of isotianil
Figure 3.9-2 Route for synthesizing isotianil
Figure 3.10-1 Chemical structure of metalaxyl-M
Figure 3.10-2 Route A for synthesizing metalaxyl-M
Figure 3.10-3 Route B for synthesizing metalaxyl-M
Figure 3.11-1 Chemical structure of metrafenone
Figure 3.11-2 Route for synthesizing metrafenone
Figure 3.12-1 Chemical structure of orysastrobin
Figure 3.12-2 Route A for synthesizing orysastrobin
Figure 3.12-3 Route B for synthesizing orysastrobin
Figure 3.12-4 Route C for synthesizing orysastrobin
Figure 3.13-1 Chemical structure of penthiopyrad
Figure 3.13-2 Route A for synthesizing penthiopyrad
Figure 3.13-3 Route B for synthesizing penthiopyrad
Figure 3.14-1 Chemical structure of prothioconazole
Figure 3.14-2 Route A for synthesizing prothioconazole
Figure 3.14-3 Route B for synthesizing prothioconazole
Figure 3.14-4 Route C for synthesizing prothioconazole
Figure 3.14-5 Route D for synthesizing prothioconazole
Figure 3.15-1 Chemical structure of pyraclostrobin
Figure 3.15-2 Route A for synthesizing pyraclostrobin
Figure 3.15-3 Route B for synthesizing pyraclostrobin
Figure 3.16-1 Chemical structure of silthiofam
Figure 3.16-2 Route for synthesizing silthiofam
Figure 3.17-1 Chemical structure of valifenalate

  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Global Ammonium Nitrate (CAS 6484-52-2) Market Professional Survey Report 2017
    Published: 23-May-2017        Price: US 3500 Onwards        Pages: 114
    This report studies Ammonium Nitrate (CAS 6484-52-2) in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Orica - Thainitrate Company - Sichuan Meifeng Chemical......
  • Termite Control Market by Species Type (Subterranean, Dry Wood, Dampwood), Control Method (Chemical, Physical & Mechanical, Biological), Application (Commercial & Industrial, Residential, Agriculture & Livestock Farms), and Region - Global Forecast to 2022
    Published: 22-May-2017        Price: US 5650 Onwards        Pages: 164
    “The termite control market is projected to grow at a CAGR of 5.6%” The termite control market is projected to grow at a CAGR of 5.6% from 2017, to reach a value of USD 4.11 billion by 2022. The market is driven by climate change, growth in public awareness, and government regulations on public and environmental healt has well on the food hygiene. Economic activities across the globe are growing at an exponential pace, along which the growing middle-class ......
  • 2017 Top 5 Seed Coating Agent Manufacturers in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 19-May-2017        Price: US 4960 Onwards        Pages: 156
    "This report will be delivered in 2-3 business days after the order is placed." The Global Seed Coating Agent market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Seed Coating Agent in Global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuses on the top 5 Seed Coating Agent Players in......
  • 2017-2022 China Seed Coating Agent Market Report (Status and Outlook)
    Published: 19-May-2017        Price: US 3360 Onwards        Pages: 116
    "This report will be delivered in 2-3 business days after the order is placed." The Seed Coating Agent market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In China market, the top players include - Bayer - Syngenta - Basf - Cargill - Rotam - Germains Seed Technology - Croda International - Bre......
  • 2017-2022 Global Top Countries Seed Coating Agent Market Report
    Published: 19-May-2017        Price: US 4960 Onwards        Pages: 156
    "This report will be delivered in 2-3 business days after the order is placed." The Global Seed Coating Agent market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Seed Coating Agent in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, Southeast Asia, Australia, Braz......
  • 2017-2022 India Seed Coating Agent Market Report (Status and Outlook)
    Published: 19-May-2017        Price: US 3360 Onwards        Pages: 116
    "This report will be delivered in 2-3 business days after the order is placed." The Seed Coating Agent market size will be XX million (USD) in 2022 in India, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In India market, the top players include - Bayer - Syngenta - Basf - Cargill - Rotam - Germains Seed Technology - Croda International - Bre......
  • 2017-2022 Japan Seed Coating Agent Market Report (Status and Outlook)
    Published: 19-May-2017        Price: US 3360 Onwards        Pages: 116
    "This report will be delivered in 2-3 business days after the order is placed." The Seed Coating Agent market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Japan market, the top players include - Bayer - Syngenta - Basf - Cargill - Rotam - Germains Seed Technology - Croda International - Bre......
  • 2017-2022 Malaysia Seed Coating Agent Market Report (Status and Outlook)
    Published: 19-May-2017        Price: US 3360 Onwards        Pages: 116
    "This report will be delivered in 2-3 business days after the order is placed." The Seed Coating Agent market size will be XX million (USD) in 2022 in Malaysia, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Malaysia market, the top players include - Bayer - Syngenta - Basf - Cargill - Rotam - Germains Seed Technology - Croda International ......
  • 2017-2022 Philippines Seed Coating Agent Market Report (Status and Outlook)
    Published: 19-May-2017        Price: US 3360 Onwards        Pages: 116
    "This report will be delivered in 2-3 business days after the order is placed." The Seed Coating Agent market size will be XX million (USD) in 2022 in Philippines, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Philippines market, the top players include - Bayer - Syngenta - Basf - Cargill - Rotam - Germains Seed Technology - Croda International......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs